Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous trading session, underperforming the S&P 500's loss of 1.67% [1] - The stock has decreased by 16.45% over the past month, compared to the Medical sector's decline of 7.36% and the S&P 500's decline of 6.15% [1] Earnings Expectations - The company is expected to report an EPS of -$0.27, which is a 46% improvement from the same quarter last year [2] - Revenue is anticipated to be $20.73 million, reflecting a 40.65% increase compared to the prior year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict an EPS of -$0.93 and revenue of $90.52 million, indicating increases of 35.42% and 21.21% respectively from the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Recursion Pharmaceuticals are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [4] Zacks Rank and Industry Position - Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold), with a 9.98% increase in the consensus EPS estimate over the last 30 days [5] - The Medical - Biomedical and Genetics industry, which includes Recursion Pharmaceuticals, has a Zacks Industry Rank of 148, placing it in the bottom 40% of over 250 industries [6]